A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications

Journal of Nuclear Medicine

Volumn 45, Issue 4, 2004, Pages 701-708

  Reilly, Raymond M ^a,b,c   Scollard, Deborah A ^a   Wang, Judy ^a   Mondal, Hridya ^a   Chen, Paul ^a   Henderson, Lee A ^d   Bowen, Barry M ^b   Vallis, Katherine A ^c,e  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Vybion Inc   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

111In; Auger electrons; Epidermal growth factor; Good manufacturing practices; Kit

Indexed keywords

DIETHYLENETRIAMINEPENTAACETIC ACID HUMAN EPIDERMAL GROWTH FACTOR IN 111; EPIDERMAL GROWTH FACTOR; INDIUM 111; PENTETIC ACID; UNCLASSIFIED DRUG; INDIUM; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BIOTECHNOLOGY; BREAST CANCER; CANCER CELL; GOOD MANUFACTURING PRACTICE; PH; PRIORITY JOURNAL; RADIOCHEMISTRY; CHEMISTRY; EQUIPMENT; EQUIPMENT DESIGN; EVALUATION; INSTRUMENTATION; ISOTOPE LABELING; MATERIALS; METHODOLOGY; QUALITY CONTROL; RADIOMETRY; RADIOTHERAPY; STANDARD; SYNTHESIS; VALIDATION STUDY;

BENCHMARKING; CHEMISTRY, PHARMACEUTICAL; EPIDERMAL GROWTH FACTOR; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MANUFACTURED MATERIALS; QUALITY CONTROL; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 2542474418     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mariani G, Bodei L, Adelstein SJ, Kassis A. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. J Nucl Med. 2000;41:1519-1521.
2. Faraggi M, Gardin I, de Labriolle-Vaylet C, Moretti J-L, Bok BD. The influence of tracer localization on the electron dose rate delivered to the cell nucleus. J Nucl Med. 1994;35:113-119.
3. Hofer KG, Harris CR, Smith MJ. Radiotoxicity of intracellular Ga-67, I-125 and H-3: nuclear versus cytoplasmic radiation effects in murine L1210 leukemia cells. Int J Radiat Biol Relat Stud Phys Chem Med. 1975;28:225-241.
4. 111In-Labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med. 2000;41:429-438.
5. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992;13:3-17.
6. Chen P, Mrkobrada M, Vallis KA, et al. Comparative antiproliferative effects of novel targeted Auger electron radiotherapy, chemotherapy and external γ-radiation on EGFR-overexpressing breast cancer cells. Nucl Med Biol. 2002;29:693-699.
7. 111In-labeled epidermal growth factor administered to athymic mice bearing EGFR-positive human breast cancer xenografts. J Nucl Med. 2003;44:1469-1478.
8. ICH Expert Working Group. Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Document no. Q7A. Geneva, Switzerland: ICH Secretariat; November 10, 2000:1-43.
9. Reagent Chemicals. Official Specification: Chloroform. 7th ed. Washington, DC: American Chemical Society; 1986:208-212.
10. United States Pharmacopoeia 25. Official Monograph: Sodium Acetate. Rockville, MD: United States Pharmacopoeial Convention; 2002:1574.
11. United States Pharmacopoeia 25. Official Monograph: Sodium Bicarbonate. Rockville, MD: United States Pharmacopoeial Convention; 2002:1575-1577.
12. National Formulary 20. Official Monograph: Edetic Acid. Rockville, MD: United States Pharmacopoeial Convention; 2002:2544.
13. 111In for imaging human breast cancer. J Nucl Med. 2000;41:903-911.
14. Hommel U, Harvey TS, Driscoll PC, Campbell ID. Human epidermal growth factor: high resolution solution structure and comparison with human transforming growth factor α. J Mol Biol. 1992;227:271-282.
15. Kuo B-S, Kusmik WF, Poole JC, et al. Pharmacokinetic evaluation of two human epidermal growth factors (hEGF51 and hEGF53) in rats. Drug Metab Dispos. 1992;20:23-30.
16. Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 1992;4:1-24.
17. Health Products and Food Branch Inspectorate. Good Manufacturing Practices Guidelines. Ottawa, Canada: Health Canada; 2002:1-86. Available at: http://www.hc-sc.gc.ca/hpfb-dgpsa/inspectorate/gmp_guidelines_2002_tc_e. html. Accessed December 31, 2002.
18. Health Products and Food Branch Inspectorate. Annex to the GMP Guidelines: Good Manufacturing Practices for Schedule C Drugs. Ottawa, Canada: Health Canada; 1999:1-12. Available at: http://www.hc-sc.gc.ca/hpfb- dgpsa/inspectorate/annex_sched_c_tc_e.html. Accessed June 30, 1999.
19. International Organization for Standardization. ISO9001. Geneva, Switzerland. 2003. Available at: http://www.iso.ch. Accessed December 15, 2000.
20. 131I- labeled epidermal growth factor. Clin Cancer Res. 1996;2:13-20.